HER2-Low Status Does Not Affect Survival Outcomes of Patients with Metastatic Breast Cancer (MBC) Undergoing First-Line Treatment with Endocrine Therapy plus Palbociclib: Results of a Multicenter, Retrospective Cohort Study
Francesca Carlino(University of Campania "Luigi Vanvitelli"), Michele Orditura(University of Campania "Luigi Vanvitelli"), S Feliciano, Benedetta Pellegrino(University of Parma), Anna Ventriglia(University of Campania "Luigi Vanvitelli"), Antonio Piccolo(University of Campania "Luigi Vanvitelli"), Vincenzo Famiglietti(University of Campania "Luigi Vanvitelli"), Anna Diana(University of Campania "Luigi Vanvitelli"), Fortunato Ciardiello(University of Campania "Luigi Vanvitelli"), L. LoBianco(University of Campania "Luigi Vanvitelli"), Francesco Giotta(Istituto Tumori Bari), Rodolfo Cangiano, Carmela Mocerino(Ospedale Antonio Cardarelli), Domenico Bilancia(Azienda Ospedaliera Ospedale San Carlo Borromeo), Ferdinando Riccardi(Ospedale Antonio Cardarelli), Giulio Antoniol(Polytechnique Montréal), Ferdinando De Vita(University of Campania "Luigi Vanvitelli")
Cited by 36
Related Papers
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
|The Lancet|2016|4.8k
ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making
|Annals of Oncology|2012|1.5k
Encorafenib, Binimetinib, and Cetuximab in <i>BRAF</i> V600E–Mutated Colorectal Cancer
|New England Journal of Medicine|2019|1.5k
Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial
|The Lancet Oncology|2016|1k
Fluorouracil, Leucovorin, and Irinotecan Plus Cetuximab Treatment and <i>RAS</i> Mutations in Colorectal Cancer
|Journal of Clinical Oncology|2015|795